Emergent BioSolutions (EBS) Receivables - Net (2010 - 2026)
Emergent BioSolutions (EBS) reported Receivables - Net of $190 million for Q2 2026, up 138.1% from $79.8 million a year earlier and up 56.3% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Receivables - Net (2010 - 2026) Analysis & Trends
At the end of FY2025, Emergent BioSolutions posted Receivables - Net of $84.2 million, down 45.5% from FY2024.
- Receivables - Net has a five-year compound annual growth rate of -18.3% (FY2020 to FY2025).
- By year, Receivables - Net came in at $154.5 million in FY2024 (-19.1%), $191 million in FY2023 (+20.0%), $159.2 million in FY2022 (-42.9%) and $278.9 million in FY2021 (+20.8%).
- The Q2 2026 figure ranks as the highest quarterly Receivables - Net since Q1 2025.
- Year over year, Receivables - Net gained in two of the last eight quarters, with an average decline of 7.5%.
- The high point for year-over-year Receivables - Net in five years was Q2 2026 (growth of 138.1%); the low point was Q2 2025 (a decline of 59.3%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $121.6 million (Q1 2026), $84.2 million (Q4 2025) and $149.5 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,143.52 Bn | 1,112.10 Bn | 19.71 Bn |
| 2 | Johnson & Johnson | 622.88 Bn | 541.41 Bn | 17.26 Bn |
| 3 | AbbVie | 510.73 Bn | 483.84 Bn | 12.70 Bn |
| 4 | Merck | 366.08 Bn | 320.46 Bn | 12.21 Bn |
| 5 | Novartis Ag | 297.30 Bn | 261.29 Bn | 11.24 Bn |
| 6 | Astrazeneca | 261.27 Bn | 234.95 Bn | 12.86 Bn |
| 7 | Amgen | 235.10 Bn | 190.50 Bn | 7.24 Bn |
| 8 | Gilead Sciences | 193.90 Bn | 168.09 Bn | 6.22 Bn |
| 9 | Pfizer | 171.85 Bn | 118.50 Bn | 10.94 Bn |
| 10 | Emergent BioSolutions | 324.05 Mn | -426.85 Mn | 137.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 190.00 Mn |
| Mar 31, 2026 | 121.60 Mn |
| Dec 31, 2025 | 84.20 Mn |
| Sep 30, 2025 | 149.50 Mn |
| Jun 30, 2025 | 79.80 Mn |
| Mar 31, 2025 | 203.70 Mn |
| Dec 31, 2024 | 154.50 Mn |
| Sep 30, 2024 | 121.30 Mn |
| Jun 30, 2024 | 196.30 Mn |
| Mar 31, 2024 | 233.50 Mn |
| Dec 31, 2023 | 191.00 Mn |
| Sep 30, 2023 | 216.50 Mn |
| Jun 30, 2023 | 290.10 Mn |
| Mar 31, 2023 | 155.90 Mn |
| Dec 31, 2022 | 159.20 Mn |
| Sep 30, 2022 | 189.20 Mn |
| Jun 30, 2022 | 175.00 Mn |
| Mar 31, 2022 | 181.80 Mn |
| Dec 31, 2021 | 278.90 Mn |
| Sep 30, 2021 | 254.60 Mn |
API Access
Emergent BioSolutions Receivables - Net API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables-net&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables-net", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables-net&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();